Immunogenicity of embryonic stem cells - rejection reaction in allogeneic transplantation

References

[1] Majumdar A., Ferber I., Lebkowski J. et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004; 22: 448-56.

[2] Drukker M., Katz G., Urbach A. et al. Characterization of the expression of MHC proteins in human embryonic stem cells. PNAS 2002; 99: 98б4-9.

[3] Zavazava N., Kabelitz D. Alloreactivity and apoptosis in graft rejection and transplantation tolerance. J. Leukoc. Biol. 2000; 68: 167-74.

[4] Сергеев B.C. Иммунологические свойства стромальных/ мезенхимальных стволовых клеток. http://celltranspl.ru/journal/publications/ ?MESSAGES[1]=SHOW_PUBLICATION&PUBLICATION_ID=803.

[5] Halloran P.F., Brosky A.P., Batiuk T.D. et al. The molecular immunology of acute rejection: an overview. Transplant. Immunol. 1993; 1: 2-27.

[6] Merad M., Hoffmann P., Ranheim E. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus- host disease. Nat. Med. 2004; 10: 510-7.

[7] Drukker M., Katchman H., Katz G. et al. Human embryonic cells and their differentiated derivatives are less susceptible for immune rejection than adult cells. Stem Cells 2005; 18 Epub.

[8] Drukker M., Benvenisty N. The immunogenicity of human embryonic stem- derived cells. Trends in Biotechnol. 2004; 22: 136-41.

[9] Bradley J., Bolton E., Pedersen R. Stem cell medecine encounters the immune system. Nat. Rev. Immunol. 2002; 2: 859-71.

RIGHTS & PERMISSIONS

Eco-Vector